TCS-OX2-29 is a selective antagonist of the orexin OX2 receptor, primarily used in scientific research to study the orexin system’s role in sleep-wake regulation. It is commonly applied in preclinical studies to investigate sleep disorders such as narcolepsy and insomnia. By selectively blocking the OX2 receptor, it helps researchers differentiate the functions of OX2 from OX1 receptors in modulating arousal, feeding behavior, and energy homeostasis. Its high selectivity makes it a valuable tool in neuropharmacology for developing potential therapeutics targeting hypersomnia or other central nervous system conditions involving orexin signaling.